Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Bioventure Management is a Germany-based investment organization founded in 2001, focusing on exclusive investments in selected life science innovations. The firm operates via a 'Club Deal' model, providing wealthy entrepreneurial families with direct co-investment opportunities in carefully selected life science companies. Since becoming active as an investment company in 2011, Bioventure Management has established a strong track record of profitable investments, translating scientific progress into measurable value for society and investors.
As of now, Bioventure Management manages approximately €70 million across six investments. The firm has successfully returned around €100 million to its investors, showcasing its effective investment strategy and execution. The organization is headquartered in Germany and primarily focuses on the European market, particularly Germany, where it has built a reputation for its rigorous selection process and active management approach.
Bioventure Management invests in economically strong and socially relevant sectors, including biotechnology, medical technology, and cell therapies. The organization emphasizes high impact and sustainable value creation through a rigorous selection process based on scientific analysis and entrepreneurial experience. Their investment strategy is centered on early-stage life science companies that demonstrate exceptional value creation potential and significant positive impact on society and patients.
The firm seeks innovations that not only advance scientific knowledge but also translate into practical applications that benefit healthcare outcomes. Bioventure Management's focus on biotechnology and medical technology aligns with its commitment to fostering advancements that can lead to improved patient care and health solutions. The firm typically engages in direct co-investment opportunities, allowing for tailored involvement in each portfolio company.
Bioventure Management's portfolio includes several notable companies that exemplify its focus on life science innovations:
Additionally, Bioventure Management has achieved notable exits, including an investment in an HMO company that was sold to Chr. Hansen at a valuation of €310 million, and a second exit valued at €1.2 billion. These successful outcomes highlight the firm's ability to identify and nurture high-potential life science ventures.
Detlef Holst: Former CEO of FrieslandCampina Germany GmbH, Detlef brings extensive experience in management and strategic development within the food and life sciences sectors.
K.-J. Klasen: A former senior employee of Dresdner Bank, K.-J. has a strong background in finance and investment, contributing valuable insights into the financial aspects of Bioventure Management's operations.
To pitch Bioventure Management, founders should use the contact form available on their website at https://www.bioventure.de/en/contact. It is important to include a detailed presentation that outlines the business model, market analysis, competitive landscape, and team qualifications. The firm appreciates thoroughness and clarity in the pitch deck.
Response times may vary, but founders should expect a professional review process. Warm introductions are beneficial, as they can enhance the likelihood of receiving a timely response.
As of April 2023, Bioventure Management has successfully completed two notable exits, including an HMO company sold to Chr. Hansen at a valuation of €310 million and another company valued at €1.2 billion at exit. These exits underscore the firm's effective investment strategy and ability to generate substantial returns for its investors.
In recent months, Bioventure Management has continued to focus on its active portfolio, which includes companies developing innovative solutions in cardiology, HIV treatment, and pneumonia therapy. The firm remains committed to identifying and supporting high-impact life science innovations.
What are Bioventure Management's investment criteria?
Bioventure Management focuses on early-stage life science companies that demonstrate exceptional value creation potential and significant positive impact on society and patients. The firm invests in sectors such as biotechnology, medical technology, and cell therapies.
How can I apply or pitch to Bioventure Management?
Founders can submit their investment inquiries through the confidential application process available on their website at https://www.bioventure.de/en/contact. It is advisable to provide a comprehensive overview of the business model, market potential, and team background in the pitch.
What makes Bioventure Management different from other investors?
Bioventure Management operates via a 'Club Deal' model, allowing wealthy entrepreneurial families to co-invest directly in selected life science companies. This model fosters a more personalized investment approach and enables active management by life science experts throughout the investment period.
What is the geographic scope of Bioventure Management's investments?
The firm primarily focuses on investments within Europe, specifically in Germany, where it has established a strong presence in the life sciences sector.
What is the typical check size for investments made by Bioventure Management?
While specific check sizes are not disclosed, the firm has a total capital of approximately €70 million across its investments, indicating a capacity for significant investments in promising life science ventures.
What kind of post-investment involvement can portfolio companies expect?
Bioventure Management adds value through active management by life science experts, providing guidance and support to portfolio companies throughout the investment period. This involvement is aimed at steering companies towards successful outcomes and maximizing their potential.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.